Trademark Overview
On Friday, July 19, 2024, a trademark application was filed for INFLECTION MEDICINE with the United States Patent and Trademark Office. The USPTO has given the INFLECTION MEDICINE trademark a serial number of 98656512. The federal status of this trademark filing is NEW APPLICATION - ASSIGNED TO EXAMINER as of Saturday, February 8, 2025. This trademark is owned by Inflection Medicine, Inc.. The INFLECTION MEDICINE trademark is filed in the Pharmaceutical Products, Computer & Software Services & Scientific Services, and Medical & Beauty Services & Agricultural Services categories with the following description:
diagnostic tests for detecting genetic diseases and disorders
medical diagnostic and treatment services, namely, whole genome sequencing testing for treating of genetic disease and disorders; clinical whole genome sequencing testing to enable the prevention, diagnosis and treatment of genetic diseases and disorders; providing medical screening for detecting genetic diseases in newborns; medical diagnosis, namely, translations of complex genomic sequencing for use in individualized patient treatment plans by healthcare providers for the diagnosis and treatment of genetically-linked diseases and conditions; providing genetic counseling and information services
development and commercialization of diagnostics for genetic diseases and disorders; development and commercialization of technology to improve clinical outcomes of individuals with genetic diseases and disorders; development and commercialization of diagnostics for identifying genetic diseases and disorders; genome sequencing services; clinical rapid whole genome sequencing test to enable the prevention, diagnosis and treatment of genetic diseases and disorders; development and commercialization of technology that provides clinical guidance; software platform for data analysis, data management, data storage, data interpretation, and report generation, all in the field of genetics and genetic testing; clinical decision support technology to assist in the translation of complex genomic sequencing for use in treatment plans by healthcare providers